Yu Bowen, Yuan Bo, Li JingZhe, Kiyomi Anna, Kikuchi Hidetomo, Hayashi Hideki, Hu Xiaomei, Okazaki Mari, Sugiura Munetoshi, Hirano Toshihiko, Fan Yingyi, Pei Xiaohua, Takagi Norio
Department of Applied Biochemistry, School of Pharmacy, Tokyo University of Pharmacy & Life Sciences, Tokyo, Japan.
Galactophore Department, Beijing University of Chinese Medicine Third Affiliated Hospital, Beijing, China.
Front Pharmacol. 2020 Jul 17;11:1087. doi: 10.3389/fphar.2020.01087. eCollection 2020.
Novel therapeutic strategies for breast cancer are urgently needed due to the sustained development of drug resistance and tumor recurrence. Trivalent arsenic derivative (arsenite, As) has been reported to induce cytotoxicity in breast cancer cells. We recently demonstrated that As plus tetrandrine (Tetra), a Chinese plant-derived alkaloid, exerted potent antitumor activity against human breast cancer cells, however, the underlying mechanisms for their action have not been well defined. In order to provide fundamental insights for understanding the action of As plus Tetra, the effects of the combined regimen on two breast cancer cell lines T47D and MDA-MB-231 were evaluated. Compared to T47D cells, MDA-MB-231 cells were much more susceptible to the synergistic cytotoxic effects of As and Tetra. Besides the induction of apoptotic/necrotic cell death, S-phase arrest and autophagic cell death were also observed in MDA-MB-231 cells. Exposure of MDA-MB-231 cells to As and Tetra caused the activation of MAPKs. Cytotoxicity of the combined regimen in MDA-MB-231 cell was significantly abrogated by SP600125, a potent c-Jun N-terminal kinase (JNK) inhibitor. However, similar abrogation was not caused by p38 and ERK inhibitors. The addition of either autophagy inhibitors (3-methyladenine or wortmannin) or SP600125 corrected the combined regimen-triggered S-phase arrest, whereas had little effect on the apoptosis/necrosis induction in the cells. Surprisingly, SP600125NC, a negative control for SP600125, significantly strengthened S-phase arrest and the cytotoxicity induced by the combined regimen. The addition of SP600125 did not alter autophagy induction. In conclusion, the cytotoxicity of As combined with Tetra was attributed to the induction of S-phase arrest, apoptotic/necrotic and autophagic cell death. The enhanced cytotoxicity of the two drugs by SP600125NC might be explained by its capability to strengthen S-phase arrest. Our results suggested that JNK and autophagy independently contributed to the cytotoxicity modulating cell cycle progression. The study further provides fundamental insights for the development of As in combination with Tetra for patients with different types of breast cancer.
由于耐药性的持续发展和肿瘤复发,乳腺癌急需新的治疗策略。据报道,三价砷衍生物(亚砷酸盐,As)可诱导乳腺癌细胞产生细胞毒性。我们最近证明,As与汉防己甲素(Tetra,一种源自中国植物的生物碱)联合使用对人乳腺癌细胞具有强大的抗肿瘤活性,然而,其作用的潜在机制尚未明确。为了深入了解As加Tetra的作用,评估了联合用药方案对两种乳腺癌细胞系T47D和MDA-MB-231的影响。与T47D细胞相比,MDA-MB-231细胞对As和Tetra的协同细胞毒性作用更敏感。除了诱导凋亡/坏死性细胞死亡外,在MDA-MB-231细胞中还观察到S期阻滞和自噬性细胞死亡。将MDA-MB-231细胞暴露于As和Tetra会导致丝裂原活化蛋白激酶(MAPKs)的激活。强效c-Jun氨基末端激酶(JNK)抑制剂SP600125可显著消除联合用药方案对MDA-MB-231细胞的细胞毒性。然而,p38和ERK抑制剂并未产生类似的消除作用。添加自噬抑制剂(3-甲基腺嘌呤或渥曼青霉素)或SP600125可纠正联合用药方案引发的S期阻滞,而对细胞凋亡/坏死诱导作用影响不大。令人惊讶的是,SP600125的阴性对照SP600125NC显著增强了联合用药方案诱导的S期阻滞和细胞毒性。添加SP600125并未改变自噬诱导。总之,As与Tetra联合使用的细胞毒性归因于S期阻滞、凋亡/坏死和自噬性细胞死亡的诱导。SP600125NC增强两种药物的细胞毒性可能是由于其增强S期阻滞的能力。我们的结果表明,JNK和自噬独立地参与调节细胞周期进程的细胞毒性作用。该研究进一步为开发As与Tetra联合用于不同类型乳腺癌患者提供了基础研究依据。